Shenzhen TargetRx Co., Ltd.

Quick facts

Phase 3 pipeline

• TGRX-326 · Diabetes
  TGRX-326 is a small molecule that targets the SGLT2 receptor.
• TGRX-678 · Diabetes
  TGRX-678 is a small molecule that targets the SGLT2 receptor.
• TKI · Oncology
  TKI inhibits tyrosine kinases to block cancer cell proliferation and survival.

Phase 1 pipeline

• [14C]TGRX-326
• [14C]TGRX-678
• cycle 1: reference drug
• cycle 1: treatment drug
• cycle 2: reference drug
• cycle 2: treatment drug
• cycle 3: reference drug
• cycle 3: treatment drug
• TGRX-1942
• TGRX-814

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Shenzhen TargetRx Co., Ltd. portfolio CI brief
• Shenzhen TargetRx Co., Ltd. pipeline updates RSS